Research Topics
Genomes and GenesSpecies | Pieter A van DoornSummaryAffiliation: Erasmus MC Country: The Netherlands Publications
| Collaborators
|
Detail Information
Publications
Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapyDeniz Güngör
Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Dr, Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands
Orphanet J Rare Dis 6:34. 2011..Our objective was to determine the survival of adults with Pompe disease not receiving ERT and to identify prognostic factors associated with survival...- Proinflammatory cytokine gene polymorphisms in irritable bowel syndromeElham Barkhordari
Department of Gastroenterology and Hepatology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
J Clin Immunol 30:74-9. 2010..Proinflammatory cytokines can play an important role in intestinal inflammation, while their production is under genetic control... - IVIG treatment and prognosis in Guillain-Barré syndromePieter A van Doorn
Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Room BA 450, s Gravendijkwal 230, Rotterdam, The Netherlands
J Clin Immunol 30:S74-8. 2010..These clinical factors were combined in a clinical prognostic scoring scale, the Erasmus GBS Outcome Scale (EGOS)... - Treatment of chronic inflammatory demyelinating polyneuropathyPieter A van Doorn
Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands
Curr Opin Neurol 17:607-13. 2004..The most up-to-date treatment options are discussed. Attention is also paid to the use of appropriate assessment scales and treatment of residual findings... - Treatment of Guillain-Barré syndrome and CIDPPieter A van Doorn
Department of Neurology, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
J Peripher Nerv Syst 10:113-27. 2005..Therefore, new treatment trials are highly indicated. This review focuses on the current and possible new treatment options that could be guided by recent results from laboratory experiments... - What's new in Guillain-Barré syndrome in 2007-2008?Pieter A van Doorn
Department of Neurology, Erasmus MC, Rotterdam, The Netherlands
J Peripher Nerv Syst 14:72-4. 2009..This suggests trials of Eculizumab in GBS should be considered. Unfortunately, there are no new randomized controlled trials in GBS to report although the unmet need is great... - How to assess new drugs for neuropathies: advances in trial design and methodologyPieter A van Doorn
Department of Neurology, Erasmus MC Rotterdam, The Netherlands
Curr Opin Neurol 21:519-26. 2008.... - Clinical features, pathogenesis, and treatment of Guillain-Barré syndromePieter A van Doorn
Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands
Lancet Neurol 7:939-50. 2008..Advances in prognostic modelling have resulted in the development of a new and simple prognostic outcome scale that might also help to guide new treatment options, particularly in patients with GBS who have a poor prognosis... - Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDPPieter A van Doorn
Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
J Peripher Nerv Syst 16:38-40. 2011.... - Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndromeBart C Jacobs
Department of Neurology, Erasmus MC, P O Box 2040, 3000 CA Rotterdam, The Netherlands
J Neuroimmunol 194:181-90. 2008..These findings support a model in which C. jejuni and H. influenzae infections induce two distinct patterns of cross-reactive antibodies with different clinical outcome... - Prediction of respiratory insufficiency in Guillain-Barré syndromeChrista Walgaard
Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
Ann Neurol 67:781-7. 2010..We aimed to develop a simple but accurate model to predict the chance of respiratory insufficiency in the acute stage of the disease based on clinical characteristics available at hospital admission... - Guillain-Barré syndrome subtypes related to Campylobacter infectionJudith Drenthen
Department of Clinical Neurophysiology, Erasmus MC, University Medical Centre Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
J Neurol Neurosurg Psychiatry 82:300-5. 2011..In The Netherlands C jejuni is the predominant type of preceding infection yet AMAN is rare. This may indicate that not all Dutch GBS patients with C jejuni infections have AMAN... - Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milkJohanna M P Van den Hout
Department of Pediatrics, Division of Metabolic Diseases and Genetics, Erasmus MC-Sophia, Rotterdam, Rotterdam, The Netherlands
Pediatrics 113:e448-57. 2004..The effect depends on residual muscle function at the start of treatment. Early start of treatment is required... - Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain-Barre syndromeKarin Geleijns
Department of Neurology, Erasmus MC, Dr Molewaterplein 50, Rotterdam, 3015 GE, The Netherlands
J Neuroimmunol 161:183-9. 2005.... - TLR4-mediated sensing of Campylobacter jejuni by dendritic cells is determined by sialylationMark L Kuijf
Department of Neurology, Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands
J Immunol 185:748-55. 2010..jejuni LOS enhances human DC activation and subsequent B cell proliferation, which may contribute to the development of cross-reactive anti-ganglioside Abs found in GBS patients following C. jejuni infection... - Effect of glucocorticoid receptor gene polymorphisms in Guillain-Barré syndromeMarieke J H J Dekker
Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
J Peripher Nerv Syst 14:75-83. 2009..In conclusion, GR haplotypes are not a susceptibility factor for GBS. However, haplotypes carrying the minor allele of the BclI polymorphism were related to the phenotype and outcome of GBS... - Mannose-binding lectin contributes to the severity of Guillain-Barré syndromeKarin Geleijns
Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
J Immunol 177:4211-7. 2006..These results support the hypothesis that complement activation mediated by MBL contributes to the extent of nerve damage in GBS, which is codetermined by the MBL2 haplotype... - Susceptibility to Guillain-Barré syndrome is not associated with CD1A and CD1E gene polymorphismsMark L Kuijf
Department of Neurology, Erasmus MC, s Gravendijkwal 230, 3015CE, Rotterdam, The Netherlands
J Neuroimmunol 205:110-2. 2008..Based on this study, CD1 polymorphisms are not a susceptibility or disease modifying factor in GBS... - Genetic polymorphisms of macrophage-mediators in Guillain-Barré syndromeKarin Geleijns
Department of Neurology, Erasmus MC, s Gravendijkwal 230, Rotterdam, The Netherlands
J Neuroimmunol 190:127-30. 2007..The MMP9 C(-1562)T and TNFA C(-863)A SNP were associated with severe weakness and poor outcome, indicating that these SNP may be one of the factors predisposing to a severe form of GBS... - Determination of pain and response to methylprednisolone in Guillain-Barré syndromeLiselotte Ruts
Dept of Neurology, Erasmus MC, Room number Ee 2230, P O Box 1738, 3000 DR, Rotterdam, The Netherlands
J Neurol 254:1318-22. 2007..Pain can be a serious problem in patients with Guillain-Barré syndrome (GBS). Different pain symptoms and the effect of methylprednisolone on pain are evaluated... - A clinical prognostic scoring system for Guillain-Barré syndromeRinske van Koningsveld
Department of Neurology, Erasmus MC, Rotterdam, Netherlands
Lancet Neurol 6:589-94. 2007..We aimed to develop and validate a scoring system based on clinical characteristics in the acute phase of GBS to predict outcome at 6 months... - AChR deficiency due to epsilon-subunit mutations: two common mutations in the NetherlandsCatharina G Faber
Department of Neurology, Maastricht University Medical Centre, PO Box 5800, 6202 AZ, Maastricht, The Netherlands
J Neurol 256:1719-23. 2009.... - Origin of ganglioside complex antibodies in Guillain-Barré syndromeMark L Kuijf
Department of Neurology, Erasmus MC, s Gravendijkwal 230, Rotterdam, The Netherlands
J Neuroimmunol 188:69-73. 2007..jejuni strain. Previous mass spectrometry studies on these LOS showed the presence of oligosaccharides with a similar structure, further supporting the hypothesis that in these patients LOS induced the ganglioside complex antibodies... - Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patientsKarin Geleijns
Department of Immunology, Erasmus Medical Centre, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
J Neuroimmunol 150:132-8. 2004..Comparison of the genotypes of 242 GBS patients and 210 healthy subjects showed that polymorphisms in CD14 and TLR4 did not confer disease susceptibility and were not associated with C. jejuni infection... - Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndromeKrista Kuitwaard
Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
Ann Neurol 66:597-603. 2009..IVIg clearance may depend on disease severity and vary between individuals, implying that this dose is suboptimal for some patients. In this study, we determined whether the pharmacokinetics of IVIg is related to outcome in GBS... - Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISAMark L Kuijf
Department of Neurology, Erasmus Medical Center, Dr Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands
J Neurol Sci 239:37-44. 2005..High IgM titers were associated with GBS and multifocal motor neuropathy. Low IgM titers had no additional diagnostic value. The INCAT-ELISA is a reliable test with additional diagnostic value in specific clinical situations... - Differentiation of hereditary spastic paraparesis from primary lateral sclerosis in sporadic adult-onset upper motor neuron syndromesFrans Brugman
Department of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands
Arch Neurol 66:509-14. 2009..Differentiation between these diseases is important for genetic counseling and prognostication... - Contribution of central and peripheral factors to residual fatigue in Guillain-Barré syndromeMarcel P J Garssen
Department of Neurology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
Muscle Nerve 36:93-9. 2007..This study thus provides further insight into the factors contributing to residual fatigue in GBS patients... - Improving fatigue assessment in immune-mediated neuropathies: the modified Rasch-built fatigue severity scaleSonja I van Nes
Department of Neurology, Erasmus Medical Centre Rotterdam, Rotterdam, The Netherlands
J Peripher Nerv Syst 14:268-78. 2009..In conclusion, a 7-item linearly weighted Rasch-built modified FSS is presented for more proper assessment of fatigue in future studies in patients with immune-mediated neuropathies... - Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuationsLiselotte Ruts
Department of Neurology, Erasmus MC, Rotterdam, The Netherlands
Neurology 65:138-40. 2005..Maintenance treatment should then be considered... - Revised normative values for grip strength with the Jamar dynamometerMartine J H Peters
Department of Neurology, Maastricht University Medical Centre, Maastricht, The Netherlands
J Peripher Nerv Syst 16:47-50. 2011..Hand dominance had no influence. Other personal factors only minimally influenced final values. This study provides revised normative GS values for the Jamar dynamometer... - Recurrences, vaccinations and long-term symptoms in GBS and CIDPKrista Kuitwaard
Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
J Peripher Nerv Syst 14:310-5. 2009..Flu vaccinations seem relatively safe. GBS and CIDP patients often experience pain, fatigue and a reduced quality of life for many years after the diagnosis... - Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE studyIngemar S J Merkies
Department of Neurology, Spaarne Hospital, Hoofddorp, The Netherlands
J Peripher Nerv Syst 15:208-15. 2010..24) was explained by impairment and activity and participation measures. Future studies are required to elucidate the impact of CIDP on disability and QoL changes, because the obtained correlations provide only partial explanation... - Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathyKrista Kuitwaard
Department of Neurology, Erasmus MC, s Gravendijkwal 230, Rotterdam, The Netherlands
Drugs 69:987-1001. 2009..An overview of these newer treatments, their mode of action, adverse effects and potential place in the spectrum of treatments for CIDP based on previous reports and their level of evidence is given... - A case of adult Pompe disease presenting with severe fatigue and selective involvement of type 1 muscle fibersLinda E M van den Berg
Department of Pediatrics, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, The Netherlands
Neuromuscul Disord 21:232-4. 2011..The cause and clinical effects of fiber type specific involvement are currently unknown, but the phenomenon might contribute to the clinical heterogeneity in Pompe disease and the variable response to enzyme replacement therapy... - First experience with enzyme replacement therapy during pregnancy and lactation in Pompe diseaseJuna M de Vries
Department of Neurology, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, The Netherlands
Mol Genet Metab 104:552-5. 2011..In this case report, the continuation of treatment with alglucosidase alfa during pregnancy and lactation has been safe for the mother and the child... - Treatment of immune neuropathiesPieter A van Doorn
Department of Neurology, Erasmus MC Rotterdam, Rotterdam, The Netherlands
Curr Opin Neurol 15:623-31. 2002..Recent therapeutic trials and the question of whether patients with mild disease or other variants of these disorders need to be treated are discussed... - Conduction velocity distribution in neurologically well-recovered but fatigued Guillain-Barré syndrome patientsMarcel P J Garssen
Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
Muscle Nerve 33:177-82. 2006..These changes were most pronounced in the subgroup of patients with the lowest fatigue scores. We therefore conclude that the observed CVD changes in patients are not likely to contribute to persisting complaints of fatigue after GBS... - Emerging drugs for Guillain-Barré syndromeChrista Walgaard
University Medical Centre, Department of Neurology, Erasmus MC, Room Ee 2230, PO Box 2040, 3000 CA Rotterdam, The Netherlands
Expert Opin Emerg Drugs 16:105-20. 2011..Under investigation are new treatment strategies with adapted IVIg dosages based on prognostic factors and more specific immunomodulation, including complement inhibitors... - Analysing the favourable effects of physical exercise: relationships between physical fitness, fatigue and functioning in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathyJohannes B J Bussmann
Department of Rehabilitation Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
J Rehabil Med 39:121-5. 2007.... - Comparison between impairment and disability scales in immune-mediated polyneuropathiesIngemar S J Merkies
Department of Neurology, University Hospital Rotterdam/Erasmus University, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands
Muscle Nerve 28:93-100. 2003..Hence, the primary use of these measures is suggested in studies of immune-mediated polyneuropathies... - Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trialIvo N van Schaik
Department of Neurology, Academic Medical Center, University of Amsterdam, Netherlands
Lancet Neurol 9:245-53. 2010..The PREDICT study aimed to compare remission rates in patients with CIDP treated with high-dose dexamethasone with rates in patients treated with standard oral prednisolone... - Immunotherapy for Guillain-Barré syndromePieter A van Doorn
Erasmus Medical Center, Department of Neurology, Dr Molewaterplein 40, 3015 Rotterdam, The Netherlands
Lancet Neurol 3:84. 2004 - The natural course of non-classic Pompe's disease; a review of 225 published casesLeon P F Winkel
Department of Paediatrics, Division of Metabolic Diseases and Genetics, Erasmus MC Sophia, Dr Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands
J Neurol 252:875-84. 2005..Studies of non-classic Pompe's disease should focus on these aspects, before enzyme replacement therapy becomes generally available... - Congenital hypomyelinating neuropathy, a long term follow-up study in an affected familyLiesbeth S Smit
Department of Pediatric Neurology, Erasmus MC Sophia Children s Hospital, Dr Molewaterplein 60, PO Box 2060, 3000 CB Rotterdam, The Netherlands
Neuromuscul Disord 18:59-62. 2008..Histopathologically there are no or thin myelin sheaths. Mutations have been described in the following genes, MPZ, EGR2, PMP22, and MTMR2. Here we describe a family with a heterozygous mutation in MPZ, confirmed in two generations... - The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patientsCarine I van Capelle
Department of Pediatrics, Division of Metabolic Diseases and Genetics, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Postbus 2060, 3000 CB, Rotterdam, The Netherlands
J Inherit Metab Dis 35:317-23. 2012..In conclusion, the Quick Motor Function Test can reliably rate clinical severity and motor function in children and adults with Pompe disease... - Hearing in adults with Pompe diseaseNadine A M E van der Beek
Department of Neurology, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, s Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
J Inherit Metab Dis 35:335-41. 2012..Therefore, we conclude that hearing loss is not a specific feature of Pompe disease in adults... - Screening for anti-ganglioside antibodies in hypocretin-deficient human narcolepsySebastiaan Overeem
Department of Neurology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
Neurosci Lett 341:13-6. 2003..However, as an autoimmune attack may be selective and/or transient, future studies are needed to ultimately refute or confirm the autoimmune hypothesis... - High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfaJuna M de Vries
Department of Neurology, Center for Lysosomal and Metabolic Diseases, Erasmus MC, Rotterdam, The Netherlands
Mol Genet Metab 101:338-45. 2010..This case demonstrates that also patients with an appreciable amount of properly folded and catalytically active endogenous acid ?-glucosidase can develop antibodies against alglucosidase alfa that affect the response to ERT... - Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathiesIngemar S J Merkies
Department of Neurology, Daniel den Hoed Cancer Center, University Hospital Rotterdam Erasmus University, Rotterdam, The Netherlands
Muscle Nerve 25:370-7. 2002..These results illustrate the clinical usefulness of the Rotterdam nine-item handicap scale under these conditions... - Selective digestive tract decontamination decreases time on ventilator in Guillain-Barré syndromeMartine E Bos Eyssen
Department of Neurology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
Neurocrit Care 15:128-33. 2011..We investigated the impact of selective decontamination of the digestive tract (SDD), an intervention that reduces hospital acquired infections in ICU patients, on duration of MV in GBS and neurological outcome at 6 months... - TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutationsHarro Seelaar
Department of Neurology, Erasmus University Medical Centre, Rotterdam, The Netherlands
Brain 130:1375-85. 2007..NII are also found in some cases of familial FTD + MND without Progranulin mutations. The observation of glial TDP-43 positive inclusions in one brain is very interesting, although their pathophysiological significance is yet unknown... - Perception of prognostic risk in patients with multiple sclerosis: the relationship with anxiety, depression, and disease-related distressA Cecile J W Janssens
Erasmus MC, Department of Neurology, PO Box 2040, 3000 CA Rotterdam, The Netherlands
J Clin Epidemiol 57:180-6. 2004..These findings underscore the importance of informing patients with chronic disorders about the short-term prognosis of important long-term consequences of disease... - Unmyelinated and myelinated skin nerve damage in Guillain-Barré syndrome: correlation with pain and recoveryLiselotte Ruts
Department of Neurology, Erasmus MC, University of Rotterdam, s Gravendijkwal 230, 3015CE Rotterdam, The Netherlands
Pain 153:399-409. 2012..IENFD declines early, remains low over time, correlates with pain severity in the acute phase, and may predict long-term disability... - Chlamydia pneumoniae and the risk for exacerbation in multiple sclerosis patientsDragan Buljevac
Department of Neurology, Erasmus MC, 3000 CA Rotterdam, The Netherlands
Ann Neurol 54:828-31. 2003..CP polymerase chain reaction was positive in most of the CP seropositive patients. No correlation was found between the anti-CP antibody increase and titers of control antibodies... - Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placeboUmesh A Badrising
Department of Neurology, Leiden University Medical Center, The Netherlands
Ann Neurol 51:369-72. 2002..Serum creatine kinase activity decreased significantly in the methotrexate group. We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased serum creatine kinase activity... - Does a carpal tunnel syndrome predict an underlying disease?Maarten C de Rijk
Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
J Neurol Neurosurg Psychiatry 78:635-7. 2007..In general, systematic screening for incident diabetes mellitus, hypothyroidism and CTD through additional blood tests seems to be of little additional value in otherwise typical cases of CTS... - Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trialRichard A C Hughes
Department of Clinical Neuroscience, King s College London, Guy s Hospital, London, UK
Lancet Neurol 7:136-44. 2008..We aimed to establish whether 10% caprylate-chromatography purified immune globulin intravenous (IGIV-C) has short-term and long-term benefit in patients with CIDP... - Fatigue: an important feature of late-onset Pompe diseaseMarloes L C Hagemans
Department of Paediatrics, Division of Metabolic Diseases and Genetics, Erasmus MC Sophia, Dr Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands
J Neurol 254:941-5. 2007..To investigate the prevalence and severity of fatigue in adult patients with Pompe disease... - Immunotherapy for Guillain-Barré syndrome: a systematic reviewRichard A C Hughes
Department of Clinical Neuroscience, King s College London, Guy s Campus, London, UK
Brain 130:2245-57. 2007..Since approximately 20% of patients die or have persistent disability despite immunotherapy, more research is needed to identify better treatment regimens and new therapeutic strategies... - Sensory exam with a quantitative tuning fork: rapid, sensitive and predictive of SNAP amplitudeIngemar S J Merkies
Neurology 63:1138; author reply 1138. 2004 - Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptorsNina M van Sorge
Department of Neurology and Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands
Ann Neurol 53:570-9. 2003..These data document the capacity of anti-GM1 IgG antibodies to activate leukocyte inflammatory functions, and suggest an important role for anti-ganglioside IgG antibodies in the pathogenesis of GBS... - Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphismsNina M van Sorge
Department of Neurology G03 228, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
J Neuroimmunol 162:157-64. 2005..Results suggest that Fc gammaRIII genotypes may represent mild disease-modifying factors in GBS... - Increased aortic stiffness in glycogenosis type 2 (Pompe's disease)Attila Nemes
Int J Cardiol 120:138-41. 2007..1 vs 5.1+/-2.6, P<0.001). CONCLUSIONS: The results of this study indicate that aortic stiffness is increased in patients with Pompe's disease. This may be due to glycogen storage in the vessel wall causing reduced vascular elasticity... - Presence or absence of cytomegalovirus in cerebrospinal fluid from patients with Guillain-Barré syndrome?Mark L Kuijf
J Infect Dis 193:1471-2; author reply 1472-3. 2006 - Multifocal motor neuropathy with abrupt onset and spontaneous recoveryCarel Bulens
J Neurol 254:966-7. 2007 - Transient hypertrichosis in a patient with Guillain-Barré syndromeLiselotte Ruts
J Peripher Nerv Syst 12:290-2. 2007 - Predicting the course of Guillain-Barré syndromePieter A van Doorn
Lancet Neurol 5:991-3. 2006